Bivalirudin ( Angiox , The Medicine 's Company , Parsippany , NJ ) , a synthetic direct thrombin inhibitor , when compared with standard antithrombotic therapy ( including unfractionated heparin [ UFH ] alone or plus a glycoprotein IIb/IIIa inhibitor ) determines a significant decrease of major and minor bleeding and similar protection against ischemic events both in elective and in urgent percutaneous coronary intervention ( PCI ) .